Publications by authors named "Bengt Simonsson"

Claim this Profile
T
Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY.
Rüdiger Hehlmann, Jorge E Cortes, Teresa Zyczynski, Carlo Gambacorti-Passerini, Stuart L Goldberg, Bengt Simonsson

Am J Hematol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY.
Stuart L Goldberg, Jorge E Cortes, Carlo Gambacorti-Passerini, Rüdiger Hehlmann, H Jean Khoury, Bengt Simonsson

Am J Hematol· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli.
Stina Söderlund, Lisa Christiansson, Inger Persson, Henrik Hjorth-Hansen, Johan Richter, Bengt Simonsson

Leuk Res· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.
William V Padula, Richard A Larson, Stacie B Dusetzina, Jane F Apperley, Rudiger Hehlmann, Bengt Simonsson

J Natl Cancer Inst· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epidemiology of chronic myeloid leukaemia: an update.
Martin Höglund, Fredrik Sandin, Bengt Simonsson

Ann Hematol· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006).
Henrik Hjorth-Hansen, Leif Stenke, Stina Söderlund, Arta Dreimane, Hans Ehrencrona, Bengt Simonsson

Eur J Haematol· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imatinib and pegylated IFN-α2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response.
Perttu Koskenvesa, Anna Kreutzman, Peter Rohon, Markus Pihlman, Emmi Vakkila, Bengt Simonsson

Eur J Haematol· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
Michele Baccarani, Michael W Deininger, Gianantonio Rosti, Andreas Hochhaus, Simona Soverini, Bengt Simonsson

Blood· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry.
Martin Höglund, Fredrik Sandin, Karin Hellström, Mats Björeman, Magnus Björkholm, Bengt Simonsson

Blood· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia.
Lisa Christiansson, Stina Söderlund, Emma Svensson, Satu Mustjoki, Mats Bengtsson, Bengt Simonsson

PLoS One· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Medical registries represent vital patient interests and should not be dismantled by stricter regulation.
Mats G Hansson, Bengt Simonsson, Nils Feltelius, Joanna Stjernschantz Forsberg, Joerg Hasford

Cancer Epidemiol· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Parental age, family size, and offspring's risk of childhood and adult acute leukemia.
Gunnar Larfors, Helene Hallböök, Bengt Simonsson

Cancer Epidemiol Biomarkers Prev· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet.
Joëlle Guilhot, Michele Baccarani, Richard E Clark, Francisco Cervantes, François Guilhot, Bengt Simonsson

Blood· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The EUTOS CML score aims to support clinical decision-making.
Verena Hoffmann, Michele Baccarani, Joerg Hasford, Joelle Guilhot, Susanne Saussele, Bengt Simonsson

Blood· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia.
Bengt Simonsson, Tobias Gedde-Dahl, Berit Markevärn, Kari Remes, Jesper Stentoft

Blood· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Both CD4+ FoxP3+ and CD4+ FoxP3- T cells from patients with B-cell malignancy express cytolytic markers and kill autologous leukaemic B cells in vitro.
Camilla A Lindqvist, Lisa H Christiansson, Ingrid Thörn, Sara Mangsbo, Gabriella Paul-Wetterberg, Bengt Simonsson

Immunology· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score.
Joerg Hasford, Michele Baccarani, Verena Hoffmann, Joelle Guilhot, Susanne Saussele, Bengt Simonsson

Blood· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interferon alpha for treatment of chronic myeloid leukemia.
Bengt Simonsson, Henrik Hjorth-Hansen, Ole Weis Bjerrum, Kimmo Porkka

Curr Drug Targets· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The European LeukemiaNet: achievements and perspectives.
Rüdiger Hehlmann, David Grimwade, Bengt Simonsson, Jane Apperley, Michele Baccarani

Haematologica· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies.
Camilla A Lindqvist, Lisa H Christiansson, Bengt Simonsson, Gunilla Enblad, Ulla Olsson-Strömberg

Immunology· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular monitoring and mutation analysis of patients with advanced phase CML and Ph+ ALL receiving dasatinib.
Ulla Olsson-Strömberg, Monica Hermansson, Tuija Lundán, Anne-Charlotte Ohm, Ida Engdahl, Bengt Simonsson

Eur J Haematol· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second-generation BCR-ABL kinase inhibitors in CML.
Bengt Simonsson, Kimmo Porkka, Johan Richter

N Engl J Med· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.
Michele Baccarani, Jorge Cortes, Fabrizio Pane, Dietger Niederwieser, Giuseppe Saglio, Bengt Simonsson

J Clin Oncol· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study.
Michele Baccarani, Gianantonio Rosti, Fausto Castagnetti, Ibrahim Haznedaroglu, Kimmo Porkka, Bengt Simonsson

Blood· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Suboptimal responses in chronic myeloid leukemia: milestones and mechanisms.
Kimmo Porkka, Satu Mustjoki, Bengt Simonsson

Expert Rev Hematol· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis